盘龙药业(002864) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was CNY 210,115,513.50, a decrease of 6.87% compared to CNY 225,625,209.86 in the same period last year[4]. - Net profit attributable to shareholders increased by 44.46% to CNY 31,147,203.65 from CNY 21,561,607.43 year-on-year[4]. - Total operating revenue for Q1 2024 was CNY 210,115,513.50, a decrease of 6.7% compared to CNY 225,625,209.86 in Q1 2023[27]. - Net profit for Q1 2024 reached CNY 31,057,891.33, representing an increase of 42.3% compared to CNY 21,812,305.64 in Q1 2023[28]. - The total comprehensive income for Q1 2024 was ¥31,057,891.33, compared to ¥21,812,305.64 in Q1 2023, marking an increase of 42.3%[29]. Cash Flow and Liquidity - The net cash flow from operating activities surged by 4,068.91% to CNY 63,478,364.28, compared to CNY 1,522,659.83 in the previous year[4]. - The total cash inflow from operating activities was ¥271,946,168.16, compared to ¥247,837,903.38 in the previous year, indicating an increase of 9.7%[31]. - The company reported cash and cash equivalents at the end of Q1 2024 amounting to ¥1,167,534,509.46, up from ¥796,263,057.99 at the end of Q1 2023, representing a growth of 46.5%[32]. - The cash flow from financing activities generated a net cash inflow of ¥49,220,138.89, compared to a net outflow of ¥10,705,969.23 in the same period last year[31]. - The company reported a financial income of CNY 8,010,392.93 in Q1 2024, compared to CNY 5,940,588.25 in Q1 2023, reflecting improved financial management[28]. Assets and Liabilities - Total assets at the end of Q1 2024 were CNY 2,189,400,325.48, reflecting a 3.03% increase from CNY 2,125,019,711.04 at the end of the previous year[4]. - Current liabilities decreased to CNY 409,175,323.89 in Q1 2024 from CNY 480,407,247.86 in Q1 2023, a reduction of 14.8%[25]. - The total equity attributable to shareholders increased to CNY 1,580,800,785.87 in Q1 2024 from CNY 1,549,045,182.15 in Q1 2023, showing growth in shareholder value[25]. Operating Costs and Expenses - The company experienced a 30.01% reduction in operating costs, amounting to CNY 79,960,232.85, attributed to changes in product sales structure[9]. - Total operating costs for Q1 2024 were CNY 179,227,823.40, down 10.5% from CNY 200,170,026.24 in the same period last year[28]. - Research and development expenses increased by 13.33% to CNY 3,717,714.19, indicating a focus on innovation and product development[9]. - Research and development expenses for Q1 2024 were CNY 3,717,714.19, up from CNY 3,280,480.41 in Q1 2023, indicating a focus on innovation[28]. - The cash outflow for purchasing goods and services was ¥68,835,945.82, down from ¥118,994,138.29 in the previous year, indicating a decrease of 42.2%[31]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 25,878, with the largest shareholder holding 34.99% of the shares[11]. - The company reported that the top ten shareholders hold a total of 9,297,483 shares, representing a significant portion of the company's equity[12]. - The basic earnings per share for Q1 2024 was ¥0.30, up from ¥0.24 in the same period last year, reflecting a growth of 25%[29]. Strategic Initiatives - The company plans to continue expanding its market presence and investing in new product development to drive future growth[4]. - The company has decided to terminate the upgrade project for the quality inspection and testing shared platform, reallocating the remaining funds to supplement working capital permanently[15]. - The company appointed Hu Qifei as the new president following the resignation of the previous general manager, Xie Xiaolin, who will continue to serve as chairman[18]. Regulatory and Project Updates - The company received administrative regulatory measures from the Shaanxi Securities Regulatory Bureau due to inaccurate disclosures regarding the progress of certain fundraising projects[20]. - The construction of the Shaanxi Province Medical Institution Preparation Center has been delayed, with the new completion date set for December 31, 2024, extending the original timeline by one year[14]. - The company’s board of directors and supervisory board approved the extension of the project timeline for the medical preparation center to enhance the effectiveness of fundraising[14].